Crinetics Pharmaceuticals CRNX Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Crinetics Pharmaceuticals (CRNX) reported accounts payable and other current liabilities (note 11) of $37.49M in Q1 2026.
- How has Crinetics Pharmaceuticals's accounts payable and other current liabilities (note 11) changed year-over-year?
- Crinetics Pharmaceuticals's accounts payable and other current liabilities (note 11) increased by 18.6% year-over-year, from $31.62M to $37.49M.
- What is the long-term trend for Crinetics Pharmaceuticals's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's accounts payable and other current liabilities (note 11) has grown at a 49.5% compound annual growth rate (CAGR), from $5.59M to $41.77M.